CML (Carboxymethyl-lysine, Ne-carboxymethyl Lysine)

CML is known to be formed from the oxidation of both carbohydrates and lipids. This makes CML a biomarker of general oxidative stress. Carboxymethyl-lysine (CML) is a well-characterized glycoxidation product that accumulates in tissues with age, and its rate of accumulation is accelerated in diabetes. Glycoxidation products are a subset of advanced glycation endproducts (AGEs) that are formed by the nonenzymatic glycation and subsequent irreversible oxidation of proteins. Oxidative stress and protein modification have been implicated in the pathogenesis of the chronic complications of diabetes, including nephropathy and atherosclerosis. The accumulation of CML in long-lived tissue such as skin collagen reflects oxidative stress over an extended period of the life-span, and has been shown to be greater in patients with diabetic complications than those without complications.\n\nApplications:\nSuitable for use in Western Blot, ELISA, Immunofluorescence and Immunohistochemistry. Other applications not tested.\n\nRecommended Dilution:\nImmunohistochemistry (Paraffin): fixation in 4% formalin; cardiac tissue sections (4mm) deparaffinised for 10min in xylene at room temperature, dehydrated by decreasing ethanol. Sections stained with haematoxylin and eosin. Blocking endogenous peroxidase used\nImmunofluorescence: After fixation in 2% phosphate-buffered glutaraldehyde solution the heart tissue was post-fixed in 1% osmium tetroxide. The tissue was dehydrated through a graded series of ethanol. 0.5-3-mm-thick sections were cut with a glass knife.\nOptimal dilutions to be determined by the researcher.\n\nPositive Control: Intramyocardial arteries\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

C1215-35

Size

100ug

Applications

ELISA, IF, IHC, WB

Hosts

Mouse

Reactivities

Hum

Form

Supplied as a liquid in PBS, 0.1% BSA, 0.02% sodium azide.

P Type

Mab

Purity

Purified by Protein G affinity chromatography.

Isotype

IgG1

References

1. Bruynzeel, AM. Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. B J of Cancer 2007: 96, 937. 2. Ciapaite J. Functioning of oxidative phosphorylation in liver mitochondria of high-fat diet fed rats. Biochim Biophys Acta. 2007, 1772:307. 3. Baidoshvili A. N(varepsilon)-(carboxymethyl)lysine depositions in intramyocardial blood vessels in human and rat acute myocardial infarction: a predictor or reflection of infarction?Arterioscler Thromb Vasc Biol. 2006, 26:2497. 4. Lieuw-a-Fa ML. Interaction of Nepsilon(carboxymethyl)lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. Thromb Haemost. 2006, 95:320. 5. van Heijst JW. Argpyrimidine-modified Heat shock protein 27 in human non-small cell lung cancer: a possible mechanism for evasion of apoptosis.Cancer Lett. 2006, 241:309. 6. Sommeijer DW. More fibrosis and thrombotic omplications but similar expression patterns of markers for coagulation and inflammation in symptomatic plaques from DM2 patients. J Histochem Cytochem. 2004, 52:1141. 7. Schalkwijk CG. Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl) lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim Biophys Acta. 2004, 221636:2. 8. Baidoshvili A. N(omega)-(carboxymethyl)lysine depositions in human aortic heart valves: similarities with atherosclerotic blood vessels. Atherosclerosis. 2004, 174:287.

Additional Info

Recognizes human CML. Species Crossreactivity: broad.